The invasive nature of glioblastoma renders them incurable by current therapeutic interventions. Using a novel invasive human glioma model, we previously identified the neurotrophin receptor p75 NTR (aka CD271) as a mediator of glioma invasion. Herein, we provide evidence that preventing phosphorylation of p75 NTR on S303 by pharmacological inhibition of PKA, or by a mutational strategy (S303G), cripples p75 NTR -mediated glioma invasion resulting in serine phosphorylation within the C-terminal PDZ-binding motif (SPV) of p75 NTR . Consistent with this, deletion (ΔSPV) or mutation (SPM) of the PDZ motif results in abrogation of p75 NTRmediated invasion. Using a peptide-based strategy, we identified PDLIM1 as a novel signaling adaptor for p75 NTR and provide the first evidence for a regulated interaction via S425 phosphorylation. Importantly, PDLIM1 was shown to interact with p75 NTR in highly invasive patient-derived glioma stem cells/tumor-initiating cells and shRNA knockdown of PDLIM1 in vitro and in vivo results in complete ablation of p75 NTR -mediated invasion. Collectively, these data demonstrate a requirement for a regulated interaction of p75 NTR with PDLIM1 and suggest that targeting either the PDZ domain interactions and/or the phosphorylation of p75 NTR by PKA could provide therapeutic strategies for patients with glioblastoma.
INTRODUCTION
Human malignant glioma is one of the most common adult primary central nervous system tumors with a median survival of only 14.6 months after diagnosis. 1, 2 A major barrier to effective treatment of glioblastoma is their highly invasive nature; they extend tendrils several centimeters away from the main tumor mass rendering them incurable by localized therapy including surgery or radiotherapy. 3, 4 Invading malignant glioma cells comprise a cell population that are genotypically and phenotypically distinct from their noninvasive counterparts, activating a number of coordinate cellular programs including those necessary for migration, invasion and survival. [4] [5] [6] [7] [8] [9] [10] [11] [12] Many individual genes have been implicated in glioma invasion and recently studies identified a subclass of glioma-expressing genes involved in cell migration and invasion that strongly correlate with poor patient survival. [13] [14] [15] [16] [17] We previously found that the neurotrophin receptor, p75
NTR , was upregulated in invasive glioma cells 18, 19 and established p75 NTR as a major contributor to their invasive nature. 18,19 p75 NTR is a transmembrane glycosylated receptor expressed by neurons, neural stem cells, astrocytes, oligodendrocytes precursors and Schwann cells 20 where it functions through interactions with several ligands and co-receptors [21] [22] [23] to mediate cell death, survival, migration and axonal growth inhibition (reviewed in Reichardt 23 and Kraemer et al. 24 ). Using an unbiased approach, we found that p75 NTR through a neurotrophin-dependent mechanism regulates the invasive behavior of glioma cells, 18, 19 a function also observed in Schwann cells, neural crest cells, melanocytes and melanoma. [25] [26] [27] [28] [29] [30] [31] Although the precise elucidation of p75 NTR downstream signaling remains unknown, a number of effector pathways have been uncovered including RhoA, 32 JNK, 33 MAPK, 34 NFκB, 26 ceramide 35 and HIF. 36 Although the exact biological implications of these signaling events are largely undefined, cellular context, localization and proteolytic processing are major determinants for p75 NTR -mediated events. 24, 37, 38 p75 NTR itself does not contain intrinsic kinase activity and instead requires association with other proteins, 24 some of which require the phosphorylation of the receptor by kinases such as the cAMP-dependent protein kinase PKA, where in cerebellar neuron phosphorylation by PKA regulates the translocation of p75 NTR to lipid rafts. 39 p75 NTR also contains protein interaction domains including a PDZ-binding motif at the extreme C-terminus of the receptor shown to interact with the Fas-associated phosphatase (FAP-1) in 293T cells 40 and Par3 during Schwann cell myelination. 41 PDZ domains have been found in a number of intracellular signaling proteins 42, 43 and, in the context of a LIM domain, can interact with the actin cytoskeleton. [44] [45] [46] [47] [48] PDLIM1 is a member of the ALP subfamily of PDZ/LIM proteins, which are postulated to have a role in actin cytoskeleton architecture.
There is mounting evidence that the neurotrophin receptor family and their respective ligands are rationale therapeutic targets. For example, p75 NTR (CD271) has been shown to be a crucial molecule driving melanoma initiation, self-renewal, invasion and metastasis, 30, 55, 56 features also associated with glioma. 18, 19, [57] [58] [59] [60] We have previously provided evidence for the targeting of p75 NTR using clinically applicable γ-secretase inhibitors that prevent intramembrane proteolysis of p75 NTR , a prerequisite for glioma invasion. 18, 19 Use of γ-secretase inhibitors have, however, generated considerable debate owing to the numerous cellular targets and unforeseen clinical complications. 61, 62 Thereby, the identification of pathways utilized by p75 NTR to drive cancer invasion and tumorigenesis would provide alternate avenues for therapeutic targeting of this signaling axis. Thus, as an alternative approach, we undertook defining the molecular signaling downstream of p75 NTR that are required to mediate glioma invasion. Herein, we provide evidence that phosphorylation of p75 NTR by PKA modulates the phosphorylation of specific amino acid residues within the cytoplasmic domain of p75 NTR resulting in a regulated interaction with PDLIM1, a novel signaling adaptor required for p75 NTR -mediated glioma invasion.
RESULTS

PKA inhibition abrogates p75 NTR -induced glioma invasion
PKA has been shown to induce serine phosphorylation of the cytoplasmic tail of p75 NTR , an event required for lipid-raft localization and downstream signaling in cerebellar neurons. 39 Consistent with a role for compartmentalized signaling cholesterol depletion by cholesterol oxidase or methyl-β-cyclodextrin abolished the ability to mediate glioma invasion in vitro (Supplementary Figure S1) suggesting a role for lipid rafts and perhaps PKA for p75 NTR -mediated glioma invasion. To determine whether PKA activity is important for p75 NTR -regulated activities in glioma, we checked whether PKA activation could promote glioma invasion. Using a PKA-selective pharmacological inhibitor KT5720, invasive U87 human glioma cells stably expressing p75 NTR (CD271) (U87p75 NTR ) were assessed for their ability to invade collagen.
Treatment of U87p75
NTR cells with KT5720 resulted in a dosedependent inhibition of invasion as compared with noninvasive U87pcDNA cells (Figure 1a ). This inhibitory effect was also observed in a highly invasive glioma cell line established by serial in vivo selection (U87R) in which p75 NTR also regulates its invasive behavior 18 ( Figure 1b) , and importantly, in three independent p75 NTR expressing patient-derived primary cultures, herein referred to as brain tumor-initiating cells ((BT042, BT134, BT147) Figures 1c  and d ). This decrease in invasion was also observed following treatment with the adenylyl cyclase inhibitor 2', 5'-dideoxyadenosine which inhibits the production of cAMP (Figure 1e ). Moreover, glioma cells expressing p75 NTR had significantly higher levels of cAMP as assessed using a transcriptional CRE-reporter assay, and transcriptional activity was further augmented by the adenylyl cyclase activator forskolin (1 μM) (Figure 1f ). Taken together, these data suggest that cAMP/PKA-induced p75 NTR phosphorylation is required for glioma invasion.
Mutation of the PKA phosphorylation site (S303G) abrogates p75 NTR -mediated invasion
In mouse cerebellar neurons, PKA phosphorylates the cytoplasmic tail of p75 NTR on serine 304 (human equivalent S303). 39 To assess the importance of S303 phosphorylation by PKA and its potential role in p75 NTR -mediated glioma invasion, U87 cells stably expressing a mutant construct of p75 NTR /CD271 with a single point mutation at S303 were generated (p75S303G; Figure 2a ) and assessed for receptor localization, topology and ability to bind neurotrophin. Previously, we demonstrated that glioma cells secrete high levels of the p75 NTR ligand BDNF and upon p75 NTR expression the ligand becomes cell associated, presumably bound to p75 NTR . 18 Flow cytometry analysis using a monoclonal antibody specific to the extracellular domain of p75 NTR confirmed plasma membrane expression and correct topography of p75S303G (Supplementary Figure S2) . In addition, glioma-derived BDNF was localized to the cell membrane, similar to the wild-type receptor, suggesting that BDNF binding was not compromised in the mutant (Supplementary Figure S3) .
The p75S303G cells were then assessed for their invasive ability. Mutation of p75 NTR at S303 resulted in a significant decrease in invasion compared with the wild-type p75 NTR despite these constructs being expressed at comparable levels in vitro (Figures 2b and c) . To confirm whether the loss of invasive ability in vitro was maintained in vivo, p75S303G cells were implanted into the brains of immunocompromised (SCID) mice. U87p75 NTR or U87pcDNA were used for comparison. Twenty-eight days after implantation, mice were killed and formalin-fixed paraffin-embedded brain sections were stained with Hematoxylin & Eosin (Figure 2d, left As we have demonstrated that p75 NTR undergoes γ-secretasemediated processing in human glioma, and this was required for p75 NTR -induced invasion, 19 the possibility existed that mutation of the PKA phosphorylation site would affect regulated intramembrane proteolysis of p75 NTR . However, as observed in Figure 2b , both the C-terminal fragment (α-secretase generated) and intracellular domain fragment (γ-secretase generated) were detected in p75S303G-expressing cells in vitro. These data suggest that in addition to intramembrane proteolysis of p75 NTR , other elements are required for the invasive behavior, such as posttranslational modifications and/or specific subcellular localization. In addition, although no difference was observed in the overall growth or viability in the presence of the PKA inhibitor KT5720 or in the PKA-defective p75 NTR -expressing glioma cells in vitro, a reproducible reduction in bromodeoxyuridine incorporation was observed in vivo (Figure 2e ) suggesting that the brain microenvironment has an impact on the growth rate or the cellular viability of these cells.
PKA regulates the phosphorylation of Serine425 in the p75 NTR -PDZ-binding motif
To confirm that S303 on p75 NTR is phosphorylated in human glioma, we assessed endogenous phosphorylation by nano-liquid chromatography-tandem mass spectrometry. Phosphorylation of S303 was detected on the wild-type receptor but no phosphorylation was detected at amino acid 303 in p75S303G cells (Figure 3a) . Phosphorylation was, however, detected on seven other serine residues (287, 303, 305, 308, 311, 313, 325 and 425) including a previously unidentified phosphorylation event on S425 of p75 NTR (Figure 3b ). This newly identified phosphorylation site is located within the extreme C-terminus of the protein and is part of a PDZ-binding motif. 40, 64 Phosphorylation of S425 was also observed in cells treated with the PKA inhibitor KT5720 suggesting a regulatory role for this specific phosphorylation event (Figure 3b ). Mutation of the p75 NTR -PDZ-binding motif reduces glioma invasion To assess the physiological relevance of phosphorylation at S425 and the importance of the C-terminal PDZ-binding domain of p75 NTR , we generated two specific p75 NTR mutants, both predicted to compromise p75 NTR binding to PDZ-containing effector proteins. 40, 64 The first construct was generated by deleting the entire PDZ-binding motif (SPV) at the extreme C-terminal of p75 NTR (ΔSPV; Figure 4a ). In the second the C-terminal valine was NTR resulted in tumors with distinctly demarcated edges. Moreover, tumors generated from glioma cells expressing either SPM or ΔSPV p75 NTR mutants were smaller and showed significant reduction of bromodeoxyuridine incorporation in vivo (Figure 4e ), a result analogous to tumors generated using the PKA phosphorylation-defective U87 cells. These data suggest that the PDZ-binding domain of p75 NTR is required for p75 NTR -mediated glioma invasion.
PDLIM1 directly interacts with the PDZ-binding motif of p75 NTR an interaction that is regulated by phosphorylation of S425 As the PDZ-binding domain was important for p75 NTR -mediated glioma invasion, we sought to identify the PDZ domain-containing 4 cells) were implanted intracerebrally into SCID mice and allowed to grow for 28 days. The mice were killed, and paraffin brain sections were stained with Hematoxylin & Eosin (H&E) or antibodies against human nucleolin or tenascin-C (brown) to visualize the tumors. Sections were counterstained with hematoxylin (blue). (e) In vivo tumor proliferation was determined by injecting bromodeoxyuridine (BrdU) into tumor-bearing mice 24 h prior to killing of the mice. Frozen brain sections were stained with an antibody against BrdU and counterstained with toluidine blue to visualize the cell nucleus. Cells that had divided during the 24 h prior to killing of the mice stained positively for BrdU, and the percentage of BrdU-positive cells was counted. Histogram represents the percentage of BrdU-positive cells in five consecutive fields. Values shown are the mean ± s.e.m. from five independent mice; asterisks (**) indicate P o0.01 as compared with control U87pcDNA (one-way ANOVA with the Neuman-Keuls post-test).
protein that binds p75 NTR to regulate invasion. Using biotinylated peptides corresponding to the C-terminus of either p75 NTR (p75WT peptide, Biotin-N-LCSESTATSPV-COOH, residues 417-427), or a valine deletion mutant of p75 NTR (p75 MT peptide, Biotin-N-LCSESTATSP-COOH, residues 417-426) as affinity reagents, we identified PDLIM1 as a potential p75 NTR -interacting protein using nano-liquid chromatography-tandem mass spectrometry (Supplementary Figure S6) . PDLIM1 (aka CLP-36, elfin, hCLIM1) was selected for further investigation based on the presence of an N-terminal PDZ domain and a C-terminal LIM domain that has been shown to associate with α-actinin-1 and α-actinin-4
46,65 and implicated in cell motility, endocytosis and cancer invasion. [66] [67] [68] [69] [70] [71] To assess the specificity of the PDLIM1-p75 NTR interaction in glioma cells, we first demonstrated that PDLIM1 bound the wildtype p75 NTR peptide but not the PDZ-binding motif mutant ( Figure 5a ). Next, based on the identification of a PKA-regulated phosphorylation on S425 (Figure 3) , we determined whether the interaction of PDLIM1 with p75 NTR was regulated by phosphorylation of S425. Therefore, p75 NTR C-terminal peptides containing an unphosphorylated S425 (SPV, Biotin-N-LCSESTATSPV-COOH, residues 417-427), a phosphorylated S425 ( Phospho SPV, Biotin-N-LCSESTAT Phospho SPV-COOH, residues 417-427) or deleted for the PDZ-binding motif (ΔSPV, Biotin-N-VESLCSESTAT-COOH, residues 414-424) were assessed for their ability to interact with PDLIM1. As shown in Figure 5b , both the Phospho SPV and ΔSPV peptide were compromised for their ability to bind PDLIM1 suggesting that PDLIM1 interacts with the C-terminal cytoplasmic domain of p75 NTR when S425 is in an unphosphorylated state. To determine whether there is a direct interaction between PDLIM1 and p75 NTR , in vitro pull-down experiments were performed using His-tagged PDLIM1 and a biotinylated-p75 NTR C-terminal peptide (Biotin-N-LCSESTATSPV-COOH, residues 417-427) ( Figure 5c ). As predicted, His-tagged PDLIM1 was found to directly bind the p75 NTR peptide containing an unphosphorylated serine at position 425 (SPV), an interaction that was dramatically reduced when S425 was phosphorylated ( Phospho SPV), when the C-terminal valine was either substituted by methionine (SPM, Biotin-N-LCSESTATSPM-COOH, residues 417-427) or deleted (ΔV, Biotin-N-SLCSESTATSP-COOH, residues 416-426) or when the entire PDZ-motif (ΔSPV) was removed. No change in binding was observed when proline within the PDZ-binding domain was substituted with aspartate (SDV, Biotin-N-LCSESTATSDV-COOH, residues 417-427). Furthermore, and consistent with these data, immunoprecipitation of lysates NTR -mediated glioma invasion requires PDLIM1 BY Ahn et al from p75
NTR -expressing glioma cells with either p75 NTR or PDLIM1 antibodies resulted in the co-precipitation of PDLIM1 and p75 NTR , respectively (Figures 5d and e, Supplementary Figure S7) . Similar results were observed using lysates from U87 cells expressing only the intracellular domain of p75 NTR or other glioma cell lines (U251, U118) expressing the p75 NTR ( Supplementary  Figures S7 and S8) . In contrast, the ability to co-precipitate PDLIM1 with the mutant alleles of p75 NTR (S303G, ΔSPV and SPM) or p75 NTR cells treated with the PKA inhibitor KT5720 was severely compromised (Figure 5d ). Most importantly, the interaction of PDLIM1 with p75 NTR was confirmed in genetically diverse patientderived glioma cells (Figure 5e ).
PDLIM1 is critical for glioma cell invasion both in vitro and in vivo As PDLIM1 possesses two functional domains, PDZ and LIM, we next assessed the requirement of these domains for the interaction with p75 NTR . To address this, HA-tagged PDLIM1 constructs lacking either the PDZ domain (ΔPDZ) or the LIM domain (ΔLIM) were generated. U87p75 glioma cells were transfected with HA-PDLIM1-ΔPDZ, HA-PDLIM1-ΔLIM or fulllength HA-PDLIM1 (Figure 6a ) and assessed for their ability to interact with p75 NTR . Although removal of either the PDZ or LIM domain of PDLIM1 compromised the ability of the protein to interact with p75 NTR , the removal of the PDZ domain resulted in a nearly complete loss of p75 NTR binding (Figure 6b ). Next, to directly assess the role of PDLIM1 in glioma behavior, U87p75 cells were stably transfected with PDLIM1 shRNA (pLK0.1-puro shPDLIM1) or a control shRNA (pLK0.1-puro). Western blot analysis and RT-PCR showed that PDLIM1 expression was dramatically reduced in U87p75 cells transfected with PDLIM1 shRNA as compared with the control shRNA (Figure 6c ). The cells stably expressing PDLIM1 shRNA were then assessed for their invasive ability in vitro where knockdown of PDLIM1 was found to significantly reduce p75 NTR -mediated invasion (Figure 6d ). To confirm this in vivo, cells were implanted into the brains of SCID mice and allowed to grow for 4 weeks. The mice were killed, and paraffin-embedded brain sections were stained with antibodies against human nuclei (Figure 6e ; brown, left panel) or PDLIM1 (Figure 6e ; brown, right panel). As predicted, knockdown of PDLIM1 resulted in complete abrogation of p75 NTR -mediated glioma invasion in vivo.
These data identify the PDZ-domain containing protein PDLIM1 as a novel p75 NTR -interacting protein that is essential for p75 NTRdependent glioma invasion, an interaction regulated by phosphorylation of S425 within the PDZ-binding domain.
DISCUSSION
The highly invasive nature of glioblastoma renders them incurable by surgery and radiotherapy, thus warranting attention to the molecular determinants regulating their invasive behavior. We previously demonstrated that the p75 NTR signaling axis is one such determinant in glioma invasion. 18, 19 Using pharmacological and loss-of-function approaches, we defined a specific role for serine phosphorylation of p75 NTR (CD271) in glioblastoma tumorigenesis NTR was confirmed in patient-derived glioma stem cells/tumor-initiating cells (BT42, BT134, BT147) by immunoprecipitation using anti-PDLIM1. Input cell lysates were assessed by western blot analysis for expression of p75 NTR and PDLIM1.
and invasion. We demonstrate that phosphorylation of p75 NTR on S303 is required for glioma invasion both in vitro and in vivo and that this regulation requires the subsequent dephosphorylation of a second serine site present in the PDZ-binding motif, S425. We provide evidence that dephosphorylation of S425 is essential for the interaction of p75 NTR with the PDZ and LIM domain containing protein PDLIM1. Moreover, we show for the first time that S425 within the canonical PDZ-binding motif of p75
NTR is phosphorylated and this regulates the interaction of p75 NTR with PDLIM1. Although it has been shown in other proteins that phosphorylation within the PDZ-binding motif increases the interaction with PDZ-containing proteins, 72, 73 we provide evidence that phosphorylation of p75 NTR on S425 prevents its binding to PDLIM1, a negative regulation that has also been observed between the β2-adrenergic receptor and NHERF1 to control recycling of the receptor. 74 In addition, we demonstrate that crippling the PDZ-binding domain, or downregulating PDLIM1, abrogates p75 NTR -mediated invasion. Importantly, our study was not limited to established cell lines, as a role for PDLIM1 in glioma invasion was also confirmed in primary patient-derived NTR and p75 NTR shPDLIM1 glioma cells (5X10 4 cells) were implanted intracerebrally into SCID mice and allowed to grow for 28 days. The mice were killed, and paraffin brain sections were stained with human nucleolin (brown) to visualize the tumors (left panel) or PDLIM1 (brown, right panel). Sections were counterstained with hematoxylin (blue).
cultures grown and maintained under neurosphere conditions, an environment that promotes the isolation of glioma cells with a cancer stem-like phenotype 60, 75, 76 and maintains the highly invasive nature of the patient tumor.
It is now clear that the spatial localization of receptors and/or downstream effector molecules is necessary for appropriate recognition and subsequent transmission of extracellular signals (for example, see reviews by Gauthier and Robbins, 77 Casaletto and McClatchey, 78 Gold et al. 79 and Hupalowska and Miaczynska 80 ). For instance, the localization of p75 NTR to lipid rafts has been shown to be important for at least some aspects of its biological activity. 39, [81] [82] [83] [84] [85] We have previously shown that regulated intramembrane proteolysis of p75 NTR is required for p75 NTRmediated glioma invasion. 19 Herein, we found that although disruption of phosphorylation at S303, or mutation of the PDZmotif (ΔSPV or SPM) results in abrogation of p75 NTR -mediated invasion, it does not compromise regulated intramembrane proteolysis of the receptor as these mutant receptors still undergo cleavage to generate both C-terminal fragment and intracellular domain fragments (Figures 2b, 3b, 4d and e) . These data therefore suggest that processing of the receptor, although previously shown to be necessary, is not sufficient to mediate the invasive behavior of glioma cells and supports a model where either the localization of the receptor and/or its cleavage products (intracellular domain), or the posttranslational modification of these products, may be required to induce glioma invasion, possibilities that are not mutually exclusive and all may be involved in some context.
The role of PDLIM1 in invasion is not limited to glioma and is involved in breast cancer cell migration, invasion and metastasis through interaction with the actin cytoskeleton, 70 a key function of many LIM domain-containing proteins. [44] [45] [46] [47] [48] Furthermore a role for p75
NTR has been established in melanoma cell migration and tumorigenesis 28, 30, 55, 56 for which we have shown an interaction of PDLIM1 with p75 NTR (Supplementary Figure S8) . In addition PDLIM1 is highly expressed in dorsal root ganglion neurons especially after nerve injury and may regulate the actin cytoskeleton during neurite outgrowth 86, 87 a function also shown to involve neurotrophins and p75 NTR . 23, 24 Although there are numerous LIM domain-containing proteins in the mammalian genome, 88 there are only 10 proteins that contain a PDZ and LIM domain. It remains to be determined whether other PDZ/LIM family members have a role in glioma invasion. Furthermore, whether other PDZ domain proteins interact with the C-terminus of p75 NTR in glioma cells is undetermined, however, it is interesting that the PDLIM PDZ domains may have unique binding specificity with their respective substrates. 89 Of note, a recent study suggests that MDA-9/ syntenin a PDZ domain-containing protein, is important in glioma invasion and pathogenesis. 90 The requirement for PDLIM1 in p75 NTR -mediated glioma invasion with its regulated binding to the receptor suggests a logical therapeutic axis for treatment of glioblastoma. Development of reversible small-molecule inhibitors that target neuron-specific PDZ domains have been proposed as a means to specifically target compartmentalized signaling within the CNS. 91 In addition, peptides targeting the PDZ domain of PTPN4, a tyrosine phosphatase, are efficient inducers of glioma cell death. 92 Thus, targeting the PDZ domain interaction of p75 NTR may provide a tissue and receptor specific therapeutic approach for patients with malignant glioma and may have global application in other cancers (that is, metastatic melanoma and breast) where p75 NTR and/or PDLIM1 have also been implicated. [28] [29] [30] 55, 93, 94 MATERIALS AND METHODS Cell culture and treatments U87 glioma cell lines were grown in Dulbecco's modified eagle's medium (Gibco-BRL, Bethesda, MD, USA) supplemented with 10% fetal bovine serum (Gibco-BRL) at 37°C in a humidified 5% CO 2 incubator. Stable transfectants were maintained in identical media with 400 μg/ml of G418 (Sigma, St. Louis, MO, USA). Brain tumor-initiating cells were established within the Brain Tumor Stem Cell Core at the University of Calgary and maintained as previously described. 19, 60 Human Metastatic melanoma cells 3S5 and 70W 97, 98 were obtained from Dr Robert Kerbel Mount Sinai Research Institute, Toronto Canada. U87 or brain tumor-initiating cells were treated with the indicated concentrations of KT5720 (1h; KT, Calbiochem, Gibbstown, NJ, USA), 2'5'-dideoxyadenosine (1 h, 30 μM; Sigma) or forskolin (30mins, 1 μM, Calbiochem), and cultured at 37°C. Control cells were treated with 1% dimethyl sulfoxide (vehicle). All cell lines were tested for mycoplasma contamination.
Mutagenesis and transfection
The human p75 NTR expression vector was constructed as described previously. 19 To generate the p75 NTR serine phosphorylation site mutant (p75S303G), the p75 NTR C-terminal PDZ-binding motif truncation mutant (p75ΔSPV) and the p75 NTR C-terminal PDZ-binding motif substitution mutant (p75SPM), site-directed mutagenesis was performed (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instructions. Constructs were inserted into pcDNA 3.1 vectors (Invitrogen, Carlsbad, CA, USA). Human PDLIM1 cDNA was purchased from Open Biosystems (Cat. no. MHS6278-202755473, Huntsville, AL, USA). Vectors encoding HA-tagged full-length PDLIM1 (residues1-329), ΔPDZ (residues 68-329) or ΔLIM mutant (residues 1-250) were cloned into the HApcDNA3.1 vector. ΔPDZ or ΔLIM mutants were obtained by PCR using the pcDNA 3.1 HA-PDLIM1plasmid as a template and verified by DNA sequencing. Transfection and selection of glioma cell lines was performed as described previously. 19 Flow cytometry and western blotting confirmed appropriate expression.
Invasion assay
Cells (2.5 × 10 4 ) were seeded on collagen-coated transwell inserts (8 μm pore size; Corning Costar, Corning, NY, USA) and incubated for 3 h at 37°C in a 5% CO 2 incubator. Media was aspirated and the cells were stained in 1% crystal violet in 95% ethanol for 1 min, rinsed in phosphatebuffered saline (PBS) and cells on the upper membrane surfaces were removed with a cotton swab. The number of cells that migrated were counted by light microscopy, and the sum of cells in five microscopic fields was recorded.
Reporter gene assay
To examine cAMP activity, transcription of a CRE-promoter was evaluated in U87 cells transfected with a CRE-luciferase reporter plasmid. U87 cells were plated in a six-well tissue culture plate at 1 × 10 4 cells per well and transfected with a pCRE-Luc reporter plasmid using lipofectamine 2000 (Invitrogen). Three days after transfection, cells were treated as outlined in each experiment. For analyses, cells were lysed in 0.5 ml of lysis buffer (Dual-Luciferase Reporter Assay System, Promega, Madison, WI, USA) and cell lysate (10 μl) was combined with 50 μl of luciferase assay reagent. Luciferase activity was measured with a GloMax-multi detection system (Promega).
Immunoprecipitation and immunoblot
Cells were lysed with RIPA buffer (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% (v/v) NP-40, protease inhibitor cocktail (Roche, Indianapolis, IN, USA), phosphatase inhibitor (Sigma)), protein quantification was determined, and proteins were resolved by sodium dodecyl sufatepolyacrylamide gel electrophoresis. Western blot analysis was performed using rabbit polyclonal anti-human p75 NTR intracellular domain (Promega), mouse monoclonal anti-β-actin (Millipore, Billerica, MA, USA) or mouse monoclonal PDLIM1 (Abcam, Cambridge, MA, USA) with the appropriate HRP-conjugated secondary antibodies (SantaCruz Biotechnology, Santa Cruz, CA, USA). For immunoprecipitation experiments, whole-cell lysates were incubated with the indicated antibody in the presence of Sepharose-Protein A/G (Sigma). Immunoprecipitates were boiled with 2 × Laemmli buffer, resolved by sodium dodecyl sufate-polyacrylamide gel electrophoresis and western blotting were performed using anti-p75 NTR (Promega), anti-PDLIM1 (Abcam) or anti-HA (Abcam) antibodies.
Reverse transcription-polymerase chain reaction (RT-PCR)
RNA from U87 cells was purified using Trizol (Invitrogen) according to the manufacturer's instructions. cDNA synthesis and analysis by PCR were performed as previously described. 18, 53 These references also list primer sequences.
Peptide affinity assay and mass spectrometric analysis For the detection of p75 NTR -interacting proteins, wild-type and mutant p75 NTR peptides, or a random peptide (control), were labeled on the amino terminus with biotin (synthesized by CanPeptide, Montréal, QC, Canada). U87 glioma cells were lysed as described above and incubated with biotinlabeled peptides for 1 h at 4°C. NeutrAvidin agarose (Thermo Scientific, Rockford, lL, USA) was added and incubated for 1 h. Peptide bound to the agarose beads was centrifuged, washed with PBS and boiled with 2 × Laemmli buffer. Proteins that bound to each peptide were resolved on a 10% sodium dodecyl sufate-polyacrylamide gel electrophoresis gel and silver-stained as described previously 95 or transferred to nitrocellulose for western blot analysis. Proteins that bound to the wild-type p75 NTR peptide and not to the mutant peptides were excised from the gel, and processed LC-MS/MS analysis as described. 95 A similar procedure was followed for the detection of serine phosphorylation on the p75 NTR mutant and wild-type receptors following immunoprecipitation with anti-p75 NTR (Promega).
Animals
Six-to 8-week-old female SCID mice (Charles River Laboratories, Shrewsbury, MA, USA) were housed in groups of three to five and maintained on a 12-h light/dark schedule with a temperature of 22°C ± 1°C and a relative humidity of 50% ± 5%. Food and water were available ad libitum. All procedures were reviewed and approved by the University of Calgary Animal Care Committee.
In vivo studies using an intracranial glioma model Glioma cells harvested using Puck's EDTA were resuspended in PBS and implanted intracerebrally into SCID mice (5 × 10 4 cells/mouse) as previously described. 18, 19, 96 Animals were randomized prior to the injection of tumor cells. At 4 weeks, BrdU was given by intraperitoneal injection 24 h prior to killing of the mice, brains were removed, fixed in 4% formalin and paraffin-embedded. Whole brain tissue sections from all animals in each group were examined by immunohistochemistry and assessed by two independent investigators, including one blinded assessment. To ensure adequate power to detect invasion, all analysis included five animals per experimental group and three independent experiments were performed.
Immunohistochemistry
Whole brain sections were fixed with cold acetone, and rehydrated through an ethanol gradient. Endogenous peroxidases were inactivated with 0.075% H 2 O 2 /methanol, and nonspecific binding blocked with Rodent Block M (Biocare Medical, Concord, CA, USA). Sections were incubated with 1:100 diluted rabbit polyclonal anti-p75 NTR antibody (Promega), mouse monoclonal anti-human nucleolin (Abcam) or antiTenascin C (Novus Biologicals, Littleton, CO, USA) in antibody diluent (Biocare Medical). Following washing with PBS, the appropriate biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA) was applied and detected using the VECTASTAIN Elite ABC kit (Vector Laboratories) and SIGMAFAST DAB (Sigma). Hematoxylin was used as a counterstain and sections were mounted with Entellan (Electron Microscopy Sciences, Hatfield, PA, USA).
Pull-down analysis of p75 NTR -PDLIM1 direct interaction
One microgram of C-terminal His-tagged recombinant PDLIM1 (Fitzgerald, Acton, MA, USA) and biotin-labeled p75 NTR C-terminal peptides (1mg/ml) (described above) were incubated in 300 μl of binding buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.05% NP-40) overnight at 4°C. NeutrAvidin agarose (Thermo Scientific) was added for 1 h, beads were centrifuged, washed with PBS and boiled with 2 × Laemmli buffer. Proteins bound to each peptide were resolved by sodium dodecyl sufate-polyacrylamide gel electrophoresis and bound PDLIM1 was detected by western blot analysis using anti-His (Abcam) or anti-PDLIM1. PDLIM1 shRNA pLKO.1-shPDLIM1 vector TRCN0000161271 (shPDLIM1; GCCTTGGTTAATT-GACTCACA) as well as pLKO.1-shControl SHC002 were purchased from Sigma and used according to the manufacturer's instructions. shPDLIM1 and shControl were transfected into U87p75 NTR cells using FuGENE 6 transfection reagent (Roche) according to the manufacturer's instructions and cells expressing the shRNA were selected in media containing Puromycin (5 μg/ml). Inhibition of PDLIM1 expression was confirmed by RT-PCR and western blot analysis.
Statistical analysis
Data were analyzed by one-way ANOVA and Student's t-test comparison, using GraphPad Instat3 software (La Jolla, CA, USA). Statistical significance was reached at Po 0.05.
